---
schema_version: "secwatch.filing_event.v1"
accession: "0001113148-23-000012"
form_type: "8-K"
ticker: null
cik: "0001113148"
company_name: "INFINITY PHARMACEUTICALS, INC."
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:21:17.550632+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Infinity Pharmaceuticals replaces CEO, CMO, and CSO; restructuring charge of $3.9M

## Summary
- CEO Adelene Perkins and CMO Dr. Robert Ilaria terminated without cause effective Sept 1, 2023; CSO Stephane Peluso also terminated.
- Seth Tasker (former SVP, Chief Business Officer) appointed CEO effective Sept 1, 2023.
- August restructuring adds 3 positions to earlier 21-headcount reduction; expects $3.9M one-time charge ($1.6M cash) in Q3 2023.
- Perkins and Ilaria signed severance agreements (9 months pay vs 12) and consulting deals to find alternative path for eganelisib after terminated MEI Pharma merger.
- $537,876 severance for Perkins; $356,362 for Ilaria; both also receive retention fees and reduced COBRA payments.

## SEC filing metadata
- accession: 0001113148-23-000012
- form_type: 8-K
- cik: 0001113148
- company_name: INFINITY PHARMACEUTICALS, INC.
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000012/0001113148-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000012/infi-20230829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001113148-23-000012
- JSON: https://secwatch.observer/filing/0001113148-23-000012.json
- Plain text: https://secwatch.observer/filing/0001113148-23-000012.txt

## Key facts
- Executive change
  Seth Tasker was appointed as Chief Executive Officer at INFINITY PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On August 29, 2023, the Board approved the appointment, effective as of September 1, 2023, of Seth Tasker, J.D., 45, as Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000012/0001113148-23-000012-index.htm
- Executive change
  Robert Ilaria, Jr. departed as Chief Medical Officer at INFINITY PHARMACEUTICALS, INC..
  - Action: terminated without cause
  - Role: Chief Medical Officer
  source text: the Board approved the termination, without cause, of the employment of Adelene Perkins as Chief Executive Officer of the Company, and Robert Ilaria, Jr., M.D., as Chief Medical Officer of the Company, effective September 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000012/0001113148-23-000012-index.htm
- Executive change
  Adelene Perkins changed role as Chief Executive Officer at INFINITY PHARMACEUTICALS, INC..
  - Action: terminated without cause
  - Role: Chief Executive Officer
  source text: the Board approved the termination, without cause, of the employment of Adelene Perkins as Chief Executive Officer of the Company, and Robert Ilaria, Jr., M.D., as Chief Medical Officer of the Company, effective September 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000012/0001113148-23-000012-index.htm
- Restructurings & Charges
  INFINITY PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.9 million (reduction of 3 positions).
  - Type: restructuring
  - Charge: approximately $3.9 million
  - Headcount: reduction of 3 positions
  source text: Restructuring is expected to be completed by the end of the third quarter of 2023. The Company expects to incur a one-time charge in the third quarter of 2023 of approximately $3.9 million in severance and restructuring costs in connection with the August Restructuring, of which approximately $1.6 million will represent cash costs. This charge primarily relates to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000111314823000012/0001113148-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.